The trajectory of the erectile dysfunction drug presents a challenging picture for investors. While the initial release generated significant gains, the end of its exclusive rights opened the door to cheaper versions, https://bookmarkfox.com/story7344254/sildenafil-and-pharma-a-risky-opportunity